GlassScriptPhysician profile
Thomas K Emig
NPI 1750485249
$26,862.77
in general payments reported to CMS, 2019-2025
84 companies · $4,478 in 2025
The $4,478 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,182 · 2020: $2,446 · 2021: $3,485 · 2022: $3,156 · 2023: $3,541 · 2024: $4,575 · 2025: $4,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $40.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,553.41 |
| Education | $40.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,560.56 | 2019-2025 | |
| Abbvie INC. | $2,720.09 | 2021-2025 | |
| Biogen, INC. | $1,723.91 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $1,211.50 | 2019-2025 | |
| Csl Behring | $1,056.11 | 2019-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $1,049.28 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $1,022.61 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Neurocrine Biosciences, INC. | $737.23 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $654.04 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $559.39 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $541.18 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $529.39 | 2019-2025 | |
| Sk Life Science, INC. | $508.84 | 2020-2025 | |
| Lundbeck LLC | $485.59 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $458.49 | 2019-2025 | Amyvid, Emgality, Kisunla |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Emig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.